Piramal Pharma Ltd reports Q2FY27 revenue of ₹2,617 crore, up 28% YoY, and raises FY27 revenue-growth outlook to 19%–20%
- EBITDA rose 72% YoY to ₹385 crore; margin expanded to 14.7% from 11.0%.
- Net profit was ₹5 crore, versus a ₹99 crore loss a year earlier and a ₹69 crore loss in Q1FY27.
- The company expects meaningfully higher profitability; no exceptional item was reported in Q2.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da812bf2-20bf-4c79-9eec-59d91a7a9cda.pdf